BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sarkar S, Popov VL, O'Connell MR, Stevenson HL, Lee BS, Obeid RA, Luthra GK, Singh P. A novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopy. Lab Invest 2017;97:1245-61. [PMID: 28414327 DOI: 10.1038/labinvest.2017.40] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Bellamkonda K, Satapathy SR, Douglas D, Chandrashekar N, Selvanesan BC, Liu M, Savari S, Jonsson G, Sjölander A. Montelukast, a CysLT1 receptor antagonist, reduces colon cancer stemness and tumor burden in a mouse xenograft model of human colon cancer. Cancer Lett 2018;437:13-24. [PMID: 30144515 DOI: 10.1016/j.canlet.2018.08.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
2 Vijai M, Baba M, Ramalingam S, Thiyagaraj A. DCLK1 and its interaction partners: An effective therapeutic target for colorectal cancer. Oncol Lett 2021;22:850. [PMID: 34733368 DOI: 10.3892/ol.2021.13111] [Reference Citation Analysis]
3 Mohammadi C, Mahdavinezhad A, Saidijam M, Bahreini F, Sedighi Pashaki A, Gholami MH, Najafi R. DCLK1 Inhibition Sensitizes Colorectal Cancer Cells to Radiation Treatment. Int J Mol Cell Med 2021;10:23-33. [PMID: 34268251 DOI: 10.22088/IJMCM.BUMS.10.1.23] [Reference Citation Analysis]
4 Qusa MH, Abdelwahed KS, Siddique AB, El Sayed KA. Comparative Gene Signature of (-)-Oleocanthal Formulation Treatments in Heterogeneous Triple Negative Breast Tumor Models: Oncological Therapeutic Target Insights. Nutrients 2021;13:1706. [PMID: 34069906 DOI: 10.3390/nu13051706] [Reference Citation Analysis]
5 Takiyama A, Tanaka T, Kazama S, Nagata H, Kawai K, Hata K, Otani K, Nishikawa T, Sasaki K, Kaneko M, Emoto S, Murono K, Takiyama H, Nozawa H. DCLK1 Expression in Colorectal Polyps Increases with the Severity of Dysplasia. In Vivo 2018;32:365-71. [PMID: 29475922 DOI: 10.21873/invivo.11247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Agulto RL, Rogers MM, Tan TC, Ramkumar A, Downing AM, Bodin H, Castro J, Nowakowski DW, Ori-McKenney KM. Autoregulatory control of microtubule binding in doublecortin-like kinase 1. Elife 2021;10:e60126. [PMID: 34310279 DOI: 10.7554/eLife.60126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Razi S, Sadeghi A, Asadi-Lari Z, Tam KJ, Kalantari E, Madjd Z. DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner. Clin Exp Med 2021;21:139-47. [PMID: 32965580 DOI: 10.1007/s10238-020-00665-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Patel O, Roy MJ, Kropp A, Hardy JM, Dai W, Lucet IS. Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1. Commun Biol 2021;4:1105. [PMID: 34545159 DOI: 10.1038/s42003-021-02631-y] [Reference Citation Analysis]
9 Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci (Basel) 2018;6:E31. [PMID: 29652830 DOI: 10.3390/medsci6020031] [Cited by in Crossref: 47] [Cited by in F6Publishing: 70] [Article Influence: 11.8] [Reference Citation Analysis]
10 Kwon MS, Chung HK, Xiao L, Yu TX, Wang SR, Piao JJ, Rao JN, Gorospe M, Wang JY. MicroRNA-195 regulates Tuft cell function in the intestinal epithelium by altering translation of DCLK1. Am J Physiol Cell Physiol 2021;320:C1042-54. [PMID: 33788631 DOI: 10.1152/ajpcell.00597.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ramkumar A, Jong BY, Ori-McKenney KM. ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins. Dev Dyn 2018;247:138-55. [PMID: 28980356 DOI: 10.1002/dvdy.24599] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 16.0] [Reference Citation Analysis]
12 Sureban SM, Berahovich R, Zhou H, Xu S, Wu L, Ding K, May R, Qu D, Bannerman-Menson E, Golubovskaya V, Houchen CW. DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers. Cancers (Basel) 2019;12:E54. [PMID: 31878090 DOI: 10.3390/cancers12010054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Subramaniam D, Angulo P, Ponnurangam S, Dandawate P, Ramamoorthy P, Srinivasan P, Iwakuma T, Weir SJ, Chastain K, Anant S. Suppressing STAT5 signaling affects osteosarcoma growth and stemness. Cell Death Dis 2020;11:149. [PMID: 32094348 DOI: 10.1038/s41419-020-2335-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
14 Kalantari E, Ghods R, Zanjani LS, Rahimi M, Eini L, Razmi M, Asadi-lari M, Madjd Z. Cytoplasmic expression of DCLK1-S, a novel DCLK1 isoform, is associated with tumor aggressiveness and worse disease-specific survival in colorectal cancer. CBM 2021. [DOI: 10.3233/cbm-210330] [Reference Citation Analysis]
15 Dai T, Hu Y, Lv F, Ozawa T, Sun X, Huang J, Han X, Kishi H, Muraguchi A, Jin A. Analysis of the clinical significance of DCLK1+ colorectal cancer using novel monoclonal antibodies against DCLK1. Onco Targets Ther. 2018;11:5047-5057. [PMID: 30174443 DOI: 10.2147/ott.s169928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Huang S, Song Y, Liang T, Zhang JR, Zhu JJ. CRISPR System-Linked Self-Assembling Nanoplatforms for Inspection and Screening of Gastric Cancer Stem Cells. Small 2021;:e2104622. [PMID: 34874610 DOI: 10.1002/smll.202104622] [Reference Citation Analysis]
17 Mohammadi Y, Tavangar SM, Saidijam M, Amini R, Etemadi K, Karimi Dermani F, Najafi R. DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c. Biomed Pharmacother 2018;103:301-7. [PMID: 29656186 DOI: 10.1016/j.biopha.2018.04.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
18 Sarkar S, O'Connell MR, Okugawa Y, Lee BS, Toiyama Y, Kusunoki M, Daboval RD, Goel A, Singh P. FOXD3 Regulates CSC Marker, DCLK1-S, and Invasive Potential: Prognostic Implications in Colon Cancer. Mol Cancer Res. 2017;15:1678-1691. [PMID: 28851816 DOI: 10.1158/1541-7786.mcr-17-0287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
19 Shafiei S, Kalantari E, Saeednejad Zanjani L, Abolhasani M, Asadi Lari MH, Madjd Z. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas. Exp Mol Pathol 2019;108:164-72. [PMID: 31028726 DOI: 10.1016/j.yexmp.2019.04.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]